RT Journal Article
SR Electronic
T1 Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.26.20044305
DO 10.1101/2020.03.26.20044305
A1 Palma, David A.
A1 Olson, Robert
A1 Harrow, Stephen
A1 Gaede, Stewart
A1 Louie, Alexander V.
A1 Haasbeek, Cornelis
A1 Mulroy, Liam
A1 Lock, Michael
A1 Rodrigues, George B.
A1 Yaremko, Brian P.
A1 Schellenberg, Devin
A1 Ahmad, Belal
A1 Senthi, Sashendra
A1 Swaminath, Anand
A1 Kopek, Neil
A1 Liu, Mitchell
A1 Moore, Karen
A1 Currie, Suzanne
A1 Schlijper, Roel
A1 Bauman, Glenn S.
A1 Laba, Joanna
A1 Qu, X. Melody
A1 Warner, Andrew
A1 Senan, Suresh
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044305.abstract
AB Purpose The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking.Methods We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between palliative standard of care (SOC) treatments (Arm 1) vs. SOC plus SABR (Arm 2). We employed a randomized phase II screening design with a primary endpoint of overall survival (OS), using an alpha of 0.20 (wherein a p-value <0.20 indicates a positive trial). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein we present long-term outcomes from the trial.Results Between 2012 and 2016, 99 patients were randomized (33 in Arm 1, 66 in Arm 2) at 10 centres internationally. Median age was 68 (range 43-89) and the majority (n=59; 60%) were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18), and prostate (n=16). Median follow-up was 51 months. Five-year OS was 17.7% in Arm 1 (95% confidence interval [CI]: 6-34%) vs. 42.3% in Arm 2 (95% CI: 28-56%; stratified log-rank p=0.006). Five-year PFS was ‘not reached’ in Arm 1 (3.2% [95% CI: 0-14%] at 4-years with last patient censored) and was 17.3% (95% CI: 8-30%) in Arm 2 (p=0.001). There were no new grade 2-5 adverse events and no differences in QOL between arms.Conclusions With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL. (NCT01446744)Funding Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst GrantCompeting Interest StatementRobert Olson has received grant funding from Varian Medical Systems, unrelated to this research project. Devin Schellenberg has received grant funding from Varian Medical Systems Inc., and honoraria from AstraZeneca, Eisai, and Merck, unrelated to this research project. Alexander Louie has received honoraria from Varian Medical Systems Inc., Astra Zeneca and RefleXion, unrelated to this research project. Anand Swaminath has received honoraria from AstraZeneca and Bristol-Meyers-Squibb, unrelated to this research project. Suresh Senan has received grant funding from ViewRay Inc and Varian Medical Systems Inc., and honoraria from AstraZeneca, Celgene, Eli Lilly and MSD, unrelated to this research project. Michael Lock has received honoraria from Abbvie, Sanofi, Bayer and Ferring, unrelated to this research project. The other authors report no conflicts of interest.Clinical TrialNCT01446744Funding StatementFunded by the Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant. The funding bodies had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe trial protocol did not include a data sharing plan, and therefore data from the trial will not be shared publicly as sharing was not included in the ethics approvals.